H. Lundbeck A/S (OTCMKTS:HLUYY – Get Rating) – Analysts at SVB Leerink boosted their FY2022 earnings per share (EPS) estimates for shares of H. Lundbeck A/S in a research report issued on Thursday, April 21st. SVB Leerink analyst M. Goodman now forecasts that the company will post earnings of $2.16 per share for the year, up from their previous estimate of $1.97. SVB Leerink also issued estimates for H. Lundbeck A/S’s FY2023 earnings at $2.95 EPS, FY2024 earnings at $3.52 EPS and FY2025 earnings at $3.68 EPS.
Other analysts have also issued research reports about the company. Barclays dropped their price objective on H. Lundbeck A/S from 200.00 to 190.00 in a research note on Tuesday, February 22nd. Zacks Investment Research upgraded H. Lundbeck A/S from a “sell” rating to a “hold” rating in a research note on Tuesday, April 12th. Credit Suisse Group dropped their price objective on H. Lundbeck A/S from 175.00 to 163.00 in a research note on Thursday, February 10th. Finally, JPMorgan Chase & Co. dropped their price objective on H. Lundbeck A/S from 250.00 to 200.00 in a research note on Tuesday, January 4th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $122.93.
The company also recently announced a dividend, which was paid on Tuesday, April 5th. Stockholders of record on Friday, March 25th were paid a dividend of $0.2044 per share. The ex-dividend date was Thursday, March 24th. This represents a dividend yield of 0.85%. H. Lundbeck A/S’s dividend payout ratio (DPR) is currently 12.20%.
About H. Lundbeck A/S (Get Rating)
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.
- Get a free copy of the StockNews.com research report on H. Lundbeck A/S (HLUYY)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.